• http://www.revobiologics.com/sites/default/files/_rotation-images/slide-3-new.jpg

    Making a Real Difference

    With an unwavering commitment to patients with rare diseases, rEVO Biologics is moving healthcare forward.

  • http://www.revobiologics.com/sites/default/files/_rotation-images/rotation_3.jpg

    Solutions for Rare Diseases

    rEVO Biologics is a rare disease company delivering on the promise of innovative therapies.

  • http://www.revobiologics.com/sites/default/files/_rotation-images/slide-2-new.jpg

    Delivering Innovative Therapies

    Through groundbreaking technology, rEVO Biologics is changing the way rare diseases are treated.

News Releases

rEVO Biologics, Inc. Provides Grant to Yale University to...

Tuesday, February 3, 2015

rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, today announced that it has provided a multi-year grant of up to $1M to Yale University to establish a Center of Advancement to further research and education in preeclampsia, and to uncover and define the best models of clinical care for the condition. rEVO is a biopharmaceutical company focused on the development of treatments for rare diseases, including early onset preeclampsia.

 

Preeclampsia is a life-threatening progressive condition that occurs in approximately five to eight percent of all pregnancies and typically occurs after the twentieth week of pregnancy. Early onset preeclampsia is a severe form that arises between 24 and 28 weeks gestation. The cause of preeclampsia is unknown, but the number of cases is growing rapidly. At present, delivery of the baby is the only known way to stop the progression of preeclampsia, which without intervention, can escalate to multiorgan failure, seizures, coma or...

Contact Us +